搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
3 天
Stifel维持Blueprint Medicines买入评级,目标价155美元
周四,Stifel重申了对Blueprint Medicines (NASDAQ:BPMC)股票的买入评级,目标价为155.00美元。该公司的评论强调了Blueprint Medicines在过敏和炎症市场的进展,特别是其主打产品Ayvakit的商业成功。
Zonebourse
24 天
Cours Blueprint Medicines Corporation
Revenue Rises 01/08 Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q2 Revenue $138.2M, vs. Street Est of $103.9M 01/08 Blueprint Medicines Corporation Reports Earnings Results for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Shooting suspect left note
Daylight saving time
1951 kidnap victim found
Robinson loses key staff
Tech ban proposed
Ga. suspect's mom indicted
California plastic bag ban
Astronauts return to Earth
Makes emergency landing
Dolphins legend Morris dies
San Francisco homelessness
Economic speech this week
Visits US ammunition plant
No govt. shutdown for now
Bulls escape MA rodeo
More troops to Middle East
No. 1 at box office again
Co-founder testifies
SpaceX plans Mars missions
To meet Vietnamese pres
Free COVID-19 tests
Donlon's homes searched
ISR raids Al Jazeera office
Former WA governor dies
Iran coal mine blast
CA firefighter held for arson
反馈